Key result
Five new-generation TAVI devices show similar rates of major adverse events at 12 months.
Why the study?
There is uncertainty regarding the comparative effectiveness and safety of contemporary transcatheter aortic valve implantation devices.
Do different new-generation TAVI devices have comparable safety and effectiveness at 12 months in patients with severe aortic stenosis?
Observational (n=1,976)
Yes
Do different new-generation TAVI devices have comparable safety and effectiveness at 12 months in patients with severe aortic stenosis?
Five leading new-generation TAVI devices demonstrate comparable 12-month rates of major adverse events, though they differ in specific complication profiles such as vascular complications and pacemaker requirements.
Answers are grounded in this paper and cite their sources.
Comparable 12-month TAVI outcomes support flexible device selection; leaves open device-specific complication trade-offs in prospective trials.
OBJECTIVES: The management of severe aortic stenosis has been revolutionized by the introduction of transcatheter aortic valve implantation (TAVI), especially in patients at intermediate, high, or prohibitive surgical risk. There is uncertainty, however, regarding the comparative effectiveness and safety of contemporary TAVI devices. METHODS: We queried detailed data from the ongoing national Italian TAVI registry and compared baseline features, procedural details, and 12-month outcomes of Acurate Neo (Boston Scientific), Evolut Pro/R (Medtronic), Lotus (Boston Scientific), Portico (Abbott Vascular), and Sapien/ Sapien S3 Ultra (Edward Lifesciences) transcatheter aortic valves. Several endpoints were collected and appraised, including the composite of death, stroke, myocardial infarction (MI), major bleeding, major vascular complication, surgical aortic valve replacement and transcatheter aortic valve reimplantation, which were deemed major adverse events (MAEs). RESULTS: A total of 1976 patients were included, with 234 treated with Acurate, 703 with Evolut, 151 with Lotus, 347 with Portico, and 541 with Sapien. Twelve-month events were not significantly different among the 5 devices, including death (P=.29) and MAE (P=.21), with the notable exception of major vascular complications, which were more common with Acurate and Sapien (P<.001) and permanent pacemaker implantation, which was more frequent with Lotus and Evolut (P<.001). Differences in MAE were more pronounced in women and subjects with prior cardiac surgery, with the lowest event rates in the Evolut group. Propensity-score adjusted analysis suggested that Acurate, Evolut, Portico, and Sapien were all associated with similarly favorable results, whereas adverse events were more evident with Lotus (P<.05). CONCLUSION: Leading current-generation TAVI devices offer similarly favorable results at mid-term follow-up.
No takes yet. Share an insight, caveat, or question.
Corcione et al. (2021) conducted an observational in Severe aortic stenosis (n=1,976). New-generation TAVI devices (Acurate, Evolut, Lotus, Portico, Sapien) vs. Compared against each other was evaluated on Major adverse events (composite of death, stroke, MI, major bleeding, major vascular complication, SAVR, and TAVI reimplantation) (p=0.21). At 12 months, five leading new-generation TAVI devices demonstrated similarly favorable results with no significant difference in major adverse events or death.
Synapse has enriched 10 related papers. Consider them for comparative context: